Moderna, Inc.NASDAQ: MRNA

Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium

· Issued by Moderna, Inc.

On 6ix: 6ix.com/news/merck-and-moderna-will-present-results-from-landmark-phase-3-interpath-001-trial-for-intismeran-autogene-plus-keytrudar-pembrolizumab-at-esmo-2026-presidential-symposium-1

Watch Moderna's latest callModerna (NASDAQ:MRNA) Q2 2026 Earnings Call · Replay · Jul 31Read the transcript of Moderna (NASDAQ:MRNA) Q2 2026 Earnings Call
Moderna's next earnings callModerna (NASDAQ:MRNA) Q3 2026 Earnings Call · Nov 6, 2026 at 8:00 AM ESTRegister

Intismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p

Moderna, Inc. on 6ix

Story so far

Earlier from Moderna

Later from Moderna

All Moderna news releases